BP
VIR icon

Ballentine Partners’s Vir Biotechnology VIR Stock Holding History

Ballentine Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,743
Closed -$59.2K – 1068
2025
Q2 		$59.2K Buy
11,743
+968
+9% +$5.19K ﹤0.01% 959
2025
Q1 		$69.8K Sell
10,775
-159
-1% -$1.41K ﹤0.01% 871
2024
Q4 		$80.3K Sell
10,934
-442
-4% -$3.49K ﹤0.01% 853
2024
Q3 		$85.2K Sell
11,376
-1,143
-9% -$9.93K ﹤0.01% 812
2024
Q2 		$111K Sell
12,519
-1,185
-9% -$11.4K ﹤0.01% 722
2024
Q1 		$139K Buy
13,704
+1,160
+9% +$11.8K ﹤0.01% 698
2023
Q4 		$126K Buy
12,544
+1,915
+18% +$17.5K ﹤0.01% 651
2023
Q3 		$99.6K Buy
+10,629
New +$152K ﹤0.01% 578

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ballentine Partners's VIR Position: Q3 2025 in Review

Ballentine Partners sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 11,743 shares — an estimated $59.2K sold.

Ballentine Partners first reported a position in VIR in Q3 2023 and held it in 8 quarters. The position peaked at $139K in Q1 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • Ballentine Partners reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Ballentine Partners sold 11,743 Vir Biotechnology shares in Q3 2025, an estimated $59.2K.
  • Ballentine Partners first reported a position in Vir Biotechnology in Q3 2023 and held it in 8 quarters.
  • Ballentine Partners's Vir Biotechnology position peaked at $139K in Q1 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Ballentine Partners's 13F filing for Q3 2025, filed 3 Nov 2025.